- \n
- Topline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025.<\/i><\/li>\n
- First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC.<\/i><\/li>\n
- IND submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy.<\/i><\/li>\n
- Projected cash runway extends into 2027<\/i><\/li>\n<\/ul>\n
BOTHELL, Wash.–(BUSINESS WIRE<\/a>)–Immunome,<\/a> Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update.\n<\/p>\n
\n\u201cImmunome\u2019s efficient execution in 2024 laid the foundation for a productive 2025,\u201d said Clay B. Siegall, Ph.D., President and Chief Executive Officer. \u201cWe are pleased with the progress of our pipeline and, with multiple programs now in clinical development, we expect that our recent financing will support multiple clinical milestones. We particularly look forward to topline data in the second half of 2025 for the RINGSIDE trial of varegacestat, which we believe will demonstrate significant benefits for patients with desmoid tumors.\n<\/p>\n
\n\u201cOur highly capable team is achieving our vision of a broad, differentiated portfolio of ADCs. We recently dosed the first patient in the Phase 1 clinical trial of IM-1021, our ROR1-targeted ADC. Three additional novel ADCs, IM-1617, IM-1335 and IM-1340, are in IND-enabling manufacturing, with additional discovery-stage programs under evaluation. We recently submitted the IND for IM-3050, our FAP radiotherapy, and anticipate initiating a Phase 1 clinical trial for that program later this year.\u201d\n<\/p>\n
Pipeline Highlights<\/b><\/p>\n
Varegacestat:<\/b> Full enrollment for the Phase 3 RINGSIDE Part B study of varegacestat for the treatment of desmoid tumors was completed in February 2024, and Immunome expects to report topline data for RINGSIDE Part B in the second half of 2025. In parallel, Immunome is performing the manufacturing and pharmacology work required to support a new drug application filing for varegacestat.\n<\/p>\n
IM-1021<\/b>:<\/b> The Phase 1 clinical trial of IM-1021 is ongoing, with the first patient dosed in February 2025. The Phase 1 trial is an open-label, multicenter dose-escalation and expansion study that is expected to include participants with advanced B-cell lymphomas and advanced solid tumors.\n<\/p>\n
IM-3050<\/b>:<\/b> Immunome recently submitted an IND for IM-3050 and expects to initiate a clinical trial for the program in the second half of 2025.\n<\/p>\n
Preclinical Pipeline<\/b> \u2013 Immunome\u2019s preclinical pipeline also includes three novel ADCs against solid tumor targets, IM-1617, IM-1340 and IM-1335, which are currently undergoing IND-enabling work, and additional, undisclosed ADCs in discovery and lead optimization.\n<\/p>\n
Fourth Quarter and Recent Corporate Highlights<\/b><\/p>\n
- \n
- \nSuccessfully completed an upsized underwritten public offering for gross proceeds of $172.5 million in January 2025, providing capital that is expected to support achievement of clinical milestones for varegacestat, IM-1021 and IM-3050 and the advancement Immunome\u2019s preclinical pipeline.\n<\/li>\n
- \nNominated IM-1617, IM-1340 and IM-1335 as novel ADC candidates, with IND-enabling work initiated in late 2024.\n<\/li>\n
- \nPresented data highlighting preclinical efficacy for IM-1021 and a differentiated profile for HC74, Immunome\u2019s proprietary TOP1 ADC payload, at the 36th<\/sup> ORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in October 2024.\n<\/li>\n<\/ul>\n
Full-year 2024 Financial Results<\/b><\/p>\n
- \n
- \nAs of December 31, 2024, cash, cash equivalents and marketable securities totaled $217.3 million, which does not include gross proceeds of $172.5 million from the January 2025 financing. Immunome\u2019s current cash runway is expected to extend into 2027.\n<\/li>\n
- \nResearch and development expenses for the year ended December 31, 2024 were $129.5 million, including stock-based compensation costs of $5.1 million.\n<\/li>\n
- \nIn-process research and development expenses for the year ended December 31, 2024 were $152.3 million. These expenses were related to Immunome\u2019s business development activity.\n<\/li>\n
- \nGeneral and administrative expenses for the year ended December 31, 2024 were $33.0 million, including stock-based compensation expense of $10.6 million.\n<\/li>\n
- \nImmunome reported a net loss of $293.0 million for the year ended December 31, 2024.\n<\/li>\n<\/ul>\n
About Immunome, Inc.<\/b><\/p>\n
\nImmunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which is the subject of a recently submitted IND. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. For more information, visit www.immunome.com<\/a>.\n<\/p>\n
Cautionary Statement Regarding Forward-Looking Statements<\/b><\/p>\n
\nStatements in this press release that are not purely historical in nature are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. We use words such as \u201cexpect,\u201d \u201cfoundation,\u201d \u201clook forward,\u201d \u201cbelieve,\u201d \u201cvision,\u201d \u201canticipates\u201d and similar expressions to identify these forward-looking statements. These forward-looking statements include Immunome\u2019s expected timing for providing topline data for the Phase 3 RINGSIDE Part B trial; Immunome\u2019s expected cash runway and ability to achieve clinical milestones; Immunome\u2019s expectation that it will enroll patients in its Phase 1 clinical trial for IM-1021 and will report resulting clinical trial data, and that it will initiate a Phase 1 clinical trial for IM-3050; Immunome\u2019s expectations regarding regulatory filings; the ability of Immunome to advance its pipeline; the potential of Immunome\u2019s ADC programs to provide first-in-class or best-in-class status; and other statements regarding management\u2019s intentions, plans, beliefs, expectations or forecasts for the future. These forward-looking statements are based on Immunome\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including the risk that Immunome will not be able to realize the benefits of its strategic transactions; the risk that regulatory approvals for Immunome\u2019s programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions; the risk that pre-clinical data may not be predictive of clinical data; the risk that Immunome\u2019s programs and product candidates fail to achieve their intended endpoints; uncertainties related to Immunome\u2019s capital requirements and Immunome\u2019s expected cash runway; Immunome\u2019s ability to grow and advance its pipeline and successfully execute on its business plan; and other risks and uncertainties indicated from time to time described in Immunome\u2019s Annual Report on Form 10-K for the year ended December 30, 2024 being filed with the SEC today, and in Immunome\u2019s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.\n<\/p>\n
\n
\n IMMUNOME, INC.<\/b><\/td>\n<\/tr>\n \n Consolidated Balance Sheets<\/b><\/td>\n<\/tr>\n \n (In thousands)<\/b><\/td>\n<\/tr>\n \n \n \n \n \n \n \n <\/tr>\n \n \n \n December 31, 2024<\/b><\/td>\n \n December 31, 2023<\/b><\/td>\n<\/tr>\n \n Assets<\/b><\/td>\n \n \n \n \n <\/tr>\n \n Current assets:<\/td>\n \n \n \n \n \n <\/tr>\n \n Cash and cash equivalents<\/td>\n \n $<\/td>\n \n \n143,351\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n $<\/td>\n \n \n98,679\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Marketable securities<\/td>\n \n \n \n \n73,952\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n39,463\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Prepaid expenses and other current assets<\/td>\n \n \n \n \n4,036\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n6,561\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Total current assets<\/td>\n \n \n \n \n221,339\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n144,703\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Property and equipment, net<\/td>\n \n \n \n \n10,113\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n2,073\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Operating right-of-use assets<\/td>\n \n \n \n \n4,278\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n1,564\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Restricted cash<\/td>\n \n \n \n \n100\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n100\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Other long-term assets<\/td>\n \n \n \n \n4,411\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n100\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Total assets<\/td>\n \n $<\/td>\n \n \n240,241\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n $<\/td>\n \n \n148,540\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Liabilities and stockholders\u2019 equity<\/b><\/td>\n \n \n \n \n \n <\/tr>\n \n Current liabilities:<\/td>\n \n \n \n \n \n <\/tr>\n \n Accounts payable<\/td>\n \n $<\/td>\n \n \n14,189\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n $<\/td>\n \n \n3,311\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Accrued expenses and other current liabilities<\/td>\n \n \n \n \n33,177\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n8,025\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Deferred revenue, current<\/td>\n \n \n \n \n6,941\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n10,493\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Total current liabilities<\/td>\n \n \n \n \n54,307\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n21,829\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Deferred revenue, non-current<\/td>\n \n \n \n \n\u2014\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n5,489\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Operating lease liabilities, net of current portion<\/td>\n \n \n \n \n4,769\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n1,340\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Total liabilities<\/td>\n \n \n \n \n59,076\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n28,658\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Stockholders\u2019 equity:<\/td>\n \n \n \n \n \n <\/tr>\n \n Preferred stock<\/td>\n \n \n \n \n\u2014\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n\u2014\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Common stock<\/td>\n \n \n \n \n6\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n4\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Additional paid-in capital<\/td>\n \n \n \n \n696,872\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n342,663\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Accumulated other comprehensive income<\/td>\n \n \n \n \n57\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n22\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Accumulated deficit<\/td>\n \n \n \n \n(515,770\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n
\n \n \n \n(222,807\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n<\/tr>\n
\n Total stockholders\u2019 equity<\/td>\n \n \n \n \n181,165\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n119,882\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Total liabilities and stockholders\u2019 equity<\/td>\n \n $<\/td>\n \n \n240,241\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n $<\/td>\n \n \n148,540\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n <\/tr>\n<\/table>\n \n
\n IMMUNOME, INC.<\/b><\/td>\n<\/tr>\n \n Consolidated Statements of Operations and Comprehensive Loss<\/b><\/td>\n<\/tr>\n \n (In thousands, except share and per share amounts)<\/b><\/td>\n<\/tr>\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n Year Ended December 31,<\/b><\/td>\n<\/tr>\n \n \n \n \n 2024<\/b><\/p>\n<\/td>\n
\n \n 2023<\/b><\/p>\n<\/td>\n<\/tr>\n
\n Collaboration revenue<\/td>\n \n $<\/td>\n \n \n9,041\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n $<\/td>\n \n \n14,018\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Operating expenses:<\/td>\n \n \n \n \n \n <\/tr>\n \n In-process research and development<\/td>\n \n \n \n \n152,344\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n80,802\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Research and development(1)<\/sup><\/td>\n \n \n \n \n129,542\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n23,089\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n General and administrative(1)<\/sup><\/td>\n \n \n \n \n32,955\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n19,657\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Total operating expenses<\/td>\n \n \n \n \n314,841\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n123,548\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Loss from operations<\/td>\n \n \n \n \n(305,800\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n
\n \n \n \n(109,530\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n<\/tr>\n
\n Interest income<\/td>\n \n \n \n \n12,837\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n2,724\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Net loss<\/td>\n \n $<\/td>\n \n \n(292,963\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n
\n $<\/td>\n \n \n(106,806\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n<\/tr>\n
\n Net loss per share, basic and diluted<\/td>\n \n $<\/td>\n \n \n(5.00\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n
\n $<\/td>\n \n \n(5.38\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n<\/tr>\n
\n Weighted-average shares outstanding, basic and diluted<\/td>\n \n \n \n \n58,639,441\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n19,843,651\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Comprehensive loss<\/td>\n \n \n \n \n \n <\/tr>\n \n Net loss<\/td>\n \n $<\/td>\n \n \n(292,963\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n
\n $<\/td>\n \n \n(106,806\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n<\/tr>\n
\n Unrealized gain on marketable securities<\/td>\n \n \n \n \n35\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n22\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Comprehensive loss<\/td>\n \n $<\/td>\n \n \n(292,928\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n
\n $<\/td>\n \n \n(106,784\n<\/p>\n<\/td>\n
\n \n)\n<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n (1) Amounts include non-cash stock-based compensation as follows (in thousands):<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n Year Ended December 31,<\/b><\/td>\n<\/tr>\n \n \n \n \n 2024<\/b><\/p>\n<\/td>\n
\n \n 2023<\/b><\/p>\n<\/td>\n<\/tr>\n
\n Research and development<\/td>\n \n $<\/td>\n \n \n5,146\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n $<\/td>\n \n \n1,981\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n General and administrative<\/td>\n \n \n \n \n10,602\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n \n \n \n4,242\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n Total share-based compensation expense<\/td>\n \n $<\/td>\n \n \n15,748\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n
\n $<\/td>\n \n \n6,223\n<\/p>\n<\/td>\n
\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n\u00a0\n<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250319932146\/en\/<\/a><\/span><\/p>\n
\nInvestor Contact:
\n
Max Rosett
\n
Chief Financial Officer
\n
investors@immunome.com<\/a><\/p>\nKEYWORDS:<\/b> United States North America Washington<\/p>\n
INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Health Pharmaceutical Oncology<\/p>\n
- First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC.<\/i><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20250319932146\/en\/2414062\/3\/Immunome_Logo_Email.jpg\"){kind=logo}
<\/td>\n<\/tr>\n